Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.rossari.com | |
Market Cap | 3,866.95 Cr. | |
Enterprise Value(EV) | 3,903.41 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 17.99 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 39.19 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 25.92 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 155.93 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 4.52 | Calculated using Price: 705.00 |
Dividend Yield | 0.07 | Period Ending 2022-03 |
No. of Shares Subscribed | 5.52 Cr. | 55,155,486 Shares |
FaceValue | 2 | |
Company Profile | ||
The company is one of the leading specialty chemicals manufacturing companies in India providing customized solutions to specific industrial and production requirements of its customers primarily in the FMCG, apparel, poultry and animal feed industries through its diversified product portfolio comprising home, personal care and performance chemicals; textile specialty chemicals; and animal health and nutrition products. The company's business is organized in three main product categories - (i) home, personal care and performance chemicals; (ii) textile specialty chemicals; and (iii) animal health and nutrition products. |
1 Day |
|
-2.09% |
1 Week |
|
-0.83% |
1 Month |
|
-1.08% |
3 Month |
|
-21.79% |
6 Month |
|
-18.32% |
1 Year |
|
-39.53% |
2 Year |
|
-19.85% |
5 Year |
|
|
10 Year |
|
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 8.60 | 8.18 | 6.99 | 27.27 | 36.33 | 41.88 | 31.83 | 23.11 | 16.17 | |
Return on Capital Employed (%) | 10.69 | 10.70 | 10.30 | 26.40 | 40.37 | 54.40 | 37.93 | 28.81 | 24.37 | |
Return on Assets (%) | 3.03 | 3.11 | 3.04 | 13.49 | 20.00 | 20.38 | 16.17 | 13.69 | 9.48 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 48 | 47 | 50 | 65 | 94 | 124 | 287 | 409 | 805 | 859 | |
Non Curr. Liab. | 8 | 9 | 7 | 2 | 4 | 37 | 69 | 59 | 251 | 113 | |
Curr. Liab. | 70 | 58 | 52 | 57 | 68 | 122 | 169 | 177 | 360 | 338 | |
Minority Int. | |||||||||||
Equity & Liab. | 125 | 114 | 109 | 124 | 166 | 283 | 525 | 645 | 1,417 | 1,310 | |
Non Curr. Assets | 50 | 46 | 46 | 47 | 60 | 123 | 178 | 263 | 742 | 654 | |
Curr. Assets | 76 | 69 | 63 | 77 | 106 | 160 | 346 | 381 | 675 | 656 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 125 | 114 | 109 | 124 | 166 | 283 | 525 | 645 | 1,417 | 1,310 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 155 | 171 | 179 | 233 | 292 | 516 | 600 | 709 | 1,483 | 1,727 | |
Other Income | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 9 | 19 | 10 | |
Total Income | 155 | 171 | 179 | 234 | 293 | 517 | 604 | 719 | 1,502 | 1,737 | |
Total Expenditure | -140 | -156 | -166 | -209 | -247 | -439 | -495 | -586 | -1,307 | -1,514 | |
PBIDT | 15 | 15 | 13 | 25 | 46 | 78 | 108 | 132 | 195 | 223 | |
Interest | -5 | -5 | -4 | -2 | -1 | -3 | -4 | -3 | -13 | -22 | |
Depreciation | -5 | -5 | -5 | -4 | -5 | -12 | -17 | -23 | -48 | -65 | |
Taxation | -1 | -1 | -1 | -3 | -11 | -18 | -23 | -27 | -39 | -39 | |
Exceptional Items | |||||||||||
PAT | 4 | 4 | 3 | 16 | 29 | 46 | 65 | 80 | 98 | 97 | |
Minority Interest | 0 | 0 | |||||||||
Share Associate | 2 | ||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 4 | 4 | 3 | 16 | 29 | 46 | 65 | 80 | 98 | 99 | |
Adjusted EPS | 9 | 8 | 8 | 36 | 66 | 9 | 13 | 15 | 18 | 18 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 24 | 71 | 57 | 48 | 29 | |
Cash Fr. Inv. | -20 | -36 | -190 | -37 | -299 | |
Cash Fr. Finan. | -5 | -29 | 157 | -25 | 292 | |
Net Change | -2 | 6 | 23 | -14 | 22 | |
Cash & Cash Eqvt | 1 | 6 | 29 | 15 | 37 |
Wed, 25 Jan 2023
Board Meeting Intimation for Inter Alia To Approve The Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31 2022. Rossari Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2023 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31 2022. |
Thu, 19 Jan 2023
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Rossari Biotech Limited has informed the Exchange regarding Allotment of 3600 Shares. |
Tue, 10 Jan 2023
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Intimation of change of name of wholly owned subsidiary of the Company. |
Fri, 27 Jan 2023 |
|
|
|
|
|